Jaguar Health Enhances Financial Position Through Debt Restructuring

Jaguar Health, Inc. has announced a strategic initiative to strengthen its balance sheet by restructuring and reducing debt obligations. The company has restructured its royalty and debt obligations related to Chicago Venture Partners L.P., effectively extinguishing 48,212 warrants. This restructuring includes a 10% reduction in royalty obligations and debt, amounting to approximately $3 million, and an extension of a credit line's maturity date by three years. No debt held by the firm now matures before July 2026.

Lisa Conte, Jaguar's CEO, confirmed that reinforcing the company's financial health is a top priority. The focus remains on advancing the global development program for crofelemer, a treatment for rare intestinal disorders. This strategy includes exploring business development opportunities and securing non-dilutive funding from potential partners. Jaguar aims to achieve significant clinical milestones through its ongoing efforts.